Related Experiment Videos
Innovative strategies in lymphoma therapy
1Division of Hematology and Hemostaseology, Department of Internal Medicine I, University of Vienna, Vienna, Austria. ulrich.jaeger@akh-wien.ac.at
Wiener Klinische Wochenschrift
|September 19, 2003
Summary
Novel biological agents are revolutionizing non-Hodgkin lymphoma (NHL) treatment. These targeted therapies, including monoclonal antibodies and new inhibitors, show promise in improving outcomes for aggressive and indolent lymphomas.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- Malignant non-Hodgkin lymphomas (NHL) treatment has evolved significantly.
- Traditional radio-chemotherapy faces limitations in efficacy and toxicity.
Purpose of the Study:
- To review advancements in 21st-century NHL treatment strategies.
- To highlight the impact of novel biological agents and targeted therapies.
Main Methods:
- Review of current literature on biological agents in NHL treatment.
- Analysis of data from phase II studies on novel therapies.
- Discussion of emerging strategies including monoclonal antibodies, radioimmunoconjugates, signal transduction inhibitors, and immunotherapy.
Main Results:
- Monoclonal antibodies (MoAbs) demonstrate efficacy alone and superior outcomes when combined with chemotherapy.
- Radioimmunoconjugates are more effective than unlabelled antibodies.
- Inhibitors of neoangiogenesis, signal transduction, and antiapoptotic mechanisms show promise.
- Vaccination and allogeneic stem cell transplantation offer long-term disease control.
Conclusions:
- Novel biological agents are revolutionizing NHL treatment, offering targeted approaches.
- Future strategies involving combinations of biological agents will improve success rates in aggressive NHL.
- These advancements may challenge the incurability paradigm for indolent lymphomas.